gefitinib has been researched along with 2-anilino-5-thiazolinone in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (2-anilino-5-thiazolinone) | Trials (2-anilino-5-thiazolinone) | Recent Studies (post-2010) (2-anilino-5-thiazolinone) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 8 | 0 | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Kendrew, J; Kettle, JG; Klinowska, T; Ogilvie, DJ; Pearson, SE; Williams, EJ; Wilson, I | 1 |
1 other study(ies) available for gefitinib and 2-anilino-5-thiazolinone
| Article | Year |
|---|---|
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; ErbB Receptors; Fluorine; Gefitinib; Humans; Inhibitory Concentration 50; Mice; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Structure-Activity Relationship; Thiazoles; Xenograft Model Antitumor Assays | 2006 |